Sign In
Buy MRK
$113.87
-1.62 (-1.40%)
At Close: Jun 18, 2026
Merck (MRK) Q3 Earnings Top Estimates, COVID Drug Boosts Sales
12:47pm, Thursday, 26'th Oct 2023
Merck (MRK) beats Q3 estimates for earnings and sales. It raises its 2023 guidance.
Merck (MRK) Q3 Earnings and Revenues Beat Estimates
09:01am, Thursday, 26'th Oct 2023
Merck (MRK) came out with quarterly earnings of $2.13 per share, beating the Zacks Consensus Estimate of $1.94 per share. This compares to earnings of $1.85 per share a year ago.
Merck results beat expectations on strong Keytruda, Gardasil and Covid drug growth
06:37am, Thursday, 26'th Oct 2023
Merck's revenue and earnings beat expectations, and it hiked its sales forecast while lowering its profit outlook.
Merck 3rd-quarter profit tops expectations on COVID pill surprise
06:33am, Thursday, 26'th Oct 2023
Merck & Co on Thursday reported higher-than-expected third-quarter sales and profit on surprisingly strong demand for its COVID-19 treatment, primarily in Japan.
Merck third-quarter results beat estimates, boosted by cancer drug and vaccine growth
06:32am, Thursday, 26'th Oct 2023
Merck & Co. on Thursday reported third-quarter results that topped analysts' expectations, powered by growth in oncology and vaccines.
Is a Surprise Coming for Merck & Co. (MRK) This Earnings Season?
12:02pm, Wednesday, 25'th Oct 2023
Merck & Co. (MRK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
GSK Gears Up for Q3 Earnings: Will It Surpass Estimates?
09:01am, Tuesday, 24'th Oct 2023
We expect GSK's specialty products like Cabenuva, Juluca, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive third-quarter sales performance.
Merck & Co. Inc. (MRK) Merck & Co. Announced Collaboration with Daiichi Sankyo and ESMO Investor Event (Transcript)
11:32am, Monday, 23'rd Oct 2023
Merck & Co. Inc. (NYSE:MRK ) October 22, 2023 1:00 PM ET Company Participants Peter Dannenbaum - VP, IR Dr. Dean Li - President, Merck Research Labs Eliav Barr - CMO & Head of Global Clinical Developm
Merck discontinues some cancer drug development with China's Sichuan Kelun
03:47am, Monday, 23'rd Oct 2023
Chinese drugmaker Sichuan Kelun Pharmaceutical Co said on Monday that Merck & Co Inc was abandoning the joint development of two candidate cancer drugs which have yet to start clinical trials.
3 Safe Dividend Stocks to Beat Inflation
09:15am, Saturday, 21'st Oct 2023
Merck may be a slow-moving behemoth, but it's setting itself up for years of earnings and dividend growth. Coca-Cola may be a big name in bottled beverages, but it wisely doesn't do its own bottling.
Trending Tickers: AT&T, Merck-Daiichi Sankyo, Klaviyo: Trending tickers October 29, 2023
05:44pm, Friday, 20'th Oct 2023
Scotiabank analysts upgrade AT&T (T) stock from "Sector Perform" to "Sector Outperform." Merck (MRK) strikes a deal worth up to $22 billion with Japanese pharmaceutical company Daiichi Sankyo (4568.T)
Merck (MRK) Inks Deal With Daiichi to Develop Cancer Drugs
02:17pm, Friday, 20'th Oct 2023
Per the terms, Merck (MRK) and Daiichi Sankyo will develop and market three ADC drugs to treat multiple types of cancer. Following the execution, Merck will make an upfront payment of $4 billion.
7 Healthcare Stocks to invest in for a Healthy Future
08:45am, Friday, 20'th Oct 2023
One of my favorite sectors will always be the healthcare sector. It is practically a basic need for all human beings and is always in constant development and growth.
Merck's Keytruda shows positive results in confirmatory trial as treatment for rare form of esophageal cancer
08:13am, Friday, 20'th Oct 2023
Merck & Co. MRK, -1.53% said Friday a late-stage trial of its blockbuster cancer drug Keytruda plus trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy achieved positive results as a t
Daiichi Sankyo shares jump on multibillion-dollar drug development deal with Merck
10:40pm, Thursday, 19'th Oct 2023
Daiichi Sankyo shares 4568, +12.21% rose sharply after the Japanese drugmaker announced a multibillion dollar deal with Merck MRK, -1.53% to jointly develop and commercialize three cancer drug candida
